T Bieber, J P Thyssen, K Reich, E L Simpson, N Katoh, A Torrelo, M De Bruin-Weller, D Thaci, R Bissonnette, M Gooderham, J Weisman, F Nunes, D Brinker, M Issa, K Holzwarth, M Gamalo, E Riedl, J Janes
BACKGROUND: Janus kinase (JAK) inhibition is a new mode of action in atopic dermatitis (AD); clarity about drug class safety considerations in the context of AD is important. Baricitinib, an oral, reversible, selective inhibitor of JAK1/JAK2, is in late-stage development for adult patients with moderate-to-severe AD. OBJECTIVE: To report pooled safety data for baricitinib in patients with moderate-to-severe AD in the clinical development program including long-term extension (LTE) studies...
February 2021: Journal of the European Academy of Dermatology and Venereology: JEADV